Cargando…
Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren’s disease: Repurposing Anti-TNF for Treating Dupuytren’s Disease (RIDD)
Dupuytren’s disease (DD) is a common fibroproliferative condition of the palmar and digital fascia of the hand; however, there is currently no approved treatment for early stage DD. The objective of this paper is to describe the methods applied to assess the cost-effectiveness of adalimumab injectio...
Autores principales: | Png, May Ee, Dritsaki, Melina, Gray, Alastair, Pinedo-Villanueva, Rafael, Rivero-Arias, Oliver, Nanchahal, Jagdeep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354323/ https://www.ncbi.nlm.nih.gov/pubmed/30756094 http://dx.doi.org/10.12688/wellcomeopenres.14936.2 |
Ejemplares similares
-
What do we know about managing Dupuytren’s disease cost-effectively?
por: Dritsaki, Melina, et al.
Publicado: (2018) -
Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren’s disease, with an embedded dose response study.
por: Nanchahal, Jagdeep, et al.
Publicado: (2017) -
Recent advances in the understanding of Dupuytren’s disease
por: Layton, Thomas, et al.
Publicado: (2019) -
Anti-tumour necrosis factor therapy for early-stage Dupuytren’s disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial
por: Nanchahal, Jagdeep, et al.
Publicado: (2022) -
Cost-effectiveness of adalimumab for early-stage Dupuytren’s disease: an economic evaluation based on a randomized controlled trial and individual-patient simulation model
por: Dakin, Helen, et al.
Publicado: (2022)